busi re-organ price pipelin read-out
conclus lower sale midpoint sole fx
benefit assum vs prior revis midpoint impli
yoy growth our/street revis sale
rang assum gener competit lyrica june patent expiri
seek month pediatr exclus lyrica
fda rais ep revis midpoint fx
benefit assum vs prior impli yoy growth lower sale
vs prior sale
report fx tailwind our/street estim
lower us higher ex-u sale vs street estimate
innov ih sale estimate higher
vaccin intern medicin partial off-set lower
sale estimate miss legaci establish product
steril inject biosimilar ep
our/street est higher sale higher non-oper
incom expect us drug price theme call due pfe
decis roll-back juli price increas state earli juli click
note titl revers juli price increas unpreced
sale modestli impact view impact sale
manag concern industri preced set
view perceiv declin pfe price leverag across portfolio
weigh investor sentiment increas need execut transform
 posit side think pfe reorgan posit improv
margin ih preserv option around spinning/divest eh and/
consum health ch segment expect contribut
ch conting decis strateg altern maintain
ep support dcf downsid target could come
clinic regulatori includ five oncolog prioriti review commerci
pfe revis sales/ep midpt impli yoy
lower sale rang
lower midpoint impli growth our/street
est note sale outlook updat sole reflect recent unfavor
chang foreign exchang rate relat dollar mid-april mid-juli
recal previous assum fx benefit midpoint revis
rang assum favor fx impact ii impact competit entri gener
 biosimilar iii defer juli price increas trump administr blueprint click
note titl revers juli price increas unpreced sale modestli impact
lower drug price goe effect whichev sooner rais adjust
dilut ep rang revis midpoint vs our/street
expect benefit fx bottom-lin vs prior assumpt continu
expect gross margin rang midpoint our/street
pfe sg rang unchang mid-point compar our/street
rais rang anticip higher spend
late-stag pipelin pfe revis exp midpoint our/street
project interest/oth incom rais prior vs our/
street recal note initi thought see note titl
thought sale miss ep vs street rang maintain interest/
incom outlook look conserv given interest/oth incom came
dividend viiv expect increas throughout year lower expect tax
our/street complet share
repurchas ytd open-market repurchas acceler share repurchas
march press releas note remain author juli
exhibit summari pfe financi rang vs our/street estim
ih/eh sale missed/beat estim
pfe sale report organic/report our/
street estim higher innov ih partial off-set lower essenti
eh sale pfe innov franchis sale came
yoy beat estim driven immunolog vaccin partial
off-set miss diseas consum healthcar
oncolog ibranc xtandi beat estim sutent
 inlyta mostli in-lin xalkori miss ibranc sale above/
our/street competit heat market immunolog
vs est xeljanz beat our/street estim enbrel eucrisa sale also
beat estim respect intern medicine/vaccin chantix/prevnar
yoy beat estim diseas miss
consum miss estimate
pfe essenti health franchis miss come yoy miss estim
driven legaci establish product steril inject partial
off-set beat peri-lo product pfe steril inject sip busi miss our/
street estim continu expect suppli disrupt start expect
start see resolut sip suppli issu also announc juli
build sip manufactur facil portag mi drug product expect
begin legaci establish product peri-lo busi miss beat
vs est premarin product miss partial off-set beat lipitor
 norvasc biosimilar sale came miss our/street
estim inflectra yoy continu face access issu us
secur ec approv trazimera biosimilar version roch herceptin trastuzumab
treatment breast cancer metastat gastric gastroesophag junction
adenocarcinoma approv follow recommend chmp may trazimera
fourth biosimilar first oncolog biosimilar secur ec approv pfe pipelin
nine distinct legaci hospira biosimilar molecul pfizer centreon sale came
yoy beat our/street est exhibit sale result vs estim
ep beat vs our/street sales/oth incom
report ep our/street est higher sale
non-oper incom sale came report
page
fx tailwind our/street estim compar estim higher sale
higher non-oper incom partial off-set higher cog higher sg
yield ep beat vs estim gross margin
our/street op-ex sg sale
compar our/street estim expens vs our/street
est sg expens came vs our/street project pfe
effect tax rate our/street dilut share count
came compar our/street estim exhibit summari
near-term catalyst includ us launch xtandi nmcrpc fda approv snda juli
ibranc pallet studi ibranc letrozol neoadjuv bc expect read fall
bavencio multipl upcom read-out ovarian renal gastric lung
bladder ovarian fda grant prioriti review pfe talazoparib parp file
embraca data gbrca breast cancer pdufa goal dec also anticip fda
action prioriti review lorlatinib nsclc august ema/jpmda
decis late earli pfe dacomitinib fda/ema review egfr nsclc
sept pdufa expect manufactur disrupt sip busi resolv
withdrew eu applic extend use sutent patient high risk recurr rcc
nephrectomi approv us june neg chmp opinion unclear point
plan re-fil near-term data read-out rivipansel voc hospit patient sickl
cell diseas read-out push like push potenti launch
page
exhibit rang vs strh consensu estim
page
midpointsuntrust estimatesconsensu statement guidancerevenu yoy weaken eur cni jpygross sg anticip spend late-stag pipelineoper incomenot providednot providednot providednot incom beyond incom adjust providednot providednot providednot epsnot providednot providednot providednot flow operationsnot providednot providednot providednot dilut relat stock-comp share yellow indic updat pfizer inc
page
valuat risk
arriv target price assum stock trade ep believ
in-lin multipl compar peer group averag warrant due pfe anem growth outlook
higher concentr sale gener eh account sale view stock
range-bound sinc manag demonstr lack urgenc wait macro
factor us tax reform and/or repatri ii binari event io clinic trial
could materi alter valuat potenti target time pfe dividend yield
aggress share repurchas add floor stock view dcf analysi yield intrins
valu per share
risk thesi includ increas competit key growth product ibranc
xalkori inlyta sutent xtandi xeljanz bavencio price pressures/high discount rebat
demand payer govern greater expect gener price compress
legaci eh product peri-lo addit risk overpay larg
biopharma acquisit convers also note sourc posit risk could includ earlier
expect transform drive sharehold return better expect perform
growth asset instanc eliqui posit blood thin market could add signific
upsid pfe allianc revenu xtandi could receiv boost sale perform
non-metastat segment prostat cancer market
compani mention note
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
